Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?
HEV antigen
anti-HEV IgM Mikrogen
anti-HEV IgM Wantai
diagnosis
hepatitis E virus
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
15
12
2019
revised:
28
01
2020
accepted:
10
02
2020
pubmed:
28
2
2020
medline:
12
8
2021
entrez:
28
2
2020
Statut:
ppublish
Résumé
Hepatitis E virus (HEV) is the leading cause of acute hepatitis worldwide. The minimum criterion for diagnosis of acute infection is detection of anti-HEV antibodies, although there are scant data on IgM duration. Our aim was to assess the persistence of HEV markers after acute self-limited hepatitis E. HEV serological tests (IgM by Mikrogen and Wantai and HEV-Ag) and HEV RNA were carried out in two cohorts: (a) patients with prior acute hepatitis E (ALT >10 x ULN plus positive IgM ± HEV RNA) currently self-limited and (b) 50 blood donors with positive HEV RNA. Among 25 cases of prior acute hepatitis E, after a median follow-up of 34 months, all presented undetectable HEV RNA. However, anti-HEV IgM remained detectable in 14 (56%) by Mikrogen, 6 (24%) by Wantai and none for HEV-Ag. Anti-HEV IgM tested positive in 80%-100% within the second year and 17%-42% over 3 years later, by Wantai and Mikrogen, respectively. Among HEV RNA-positive donors, 12 (25%) tested positive for either IgM by Mikrogen or Wantai, 9 (18%) for both and 18 (36%) for HEV-Ag. HEV-Ag positivity was more likely as HEV RNA was higher (14% if <2.2 log IU/mL; 64% if RNA ≥ 3.7). Overall, HEV-Ag performed best, with a positive predictive value of 100% and diagnostic accuracy of 57%. Anti-HEV IgM exhibited unexpectedly long persistence after a self-limited acute hepatitis E. HEV-Ag had the best performance and could be especially useful in settings where HEV RNA is not available.
Substances chimiques
Hepatitis Antibodies
0
Immunoglobulin M
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
747-753Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
World Health Organization. Hepatitis E virus. http://www.who.int/news-room/fact-sheets/detail/hepatitis-e. Accessed July 3, 2017.
(ECDC) ECfDPaC. Hepatitis E in the EU/EEA, 2005-2015. 2017.
Kokki I, Smith D, Simmonds P, et al. Hepatitis E virus is the leading cause of acute viral hepatitis in Lothian Scotland. New Microbes New Infect. 2016;10:6-12.
Doting MHE, Weel J, Niesters HGM, Riezebos-Brilman A, Brandenburg A. The added value of hepatitis E diagnostics in determining causes of hepatitis in routine diagnostic settings in the Netherlands. Clin Microbiol Infec. 2017;23(9):667-671.
Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet (London, England). 2010;376(9744):895-902.
Sauleda S, Ong E, Bes M, et al. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). Transfusion. 2015;55(5):972-979.
Dalton HR, Kamar N, Baylis SA, Moradpour D, Wedemeyer H, Negro F. Clinical EASL Practice guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256-1271.
European Centre for Disease Prevention and Control. Options for National Testing and Surveillance for Hepatitis E Virus in the EU/EEA - Operational Guidance. Stockholm: ECDC;2019.
Krawczynski K, Meng XJ, Rybczynska J. Pathogenetic elements of hepatitis E and animal models of HEV infection. Virus Res. 2011;161(1):78-83.
Avellon A, Morago L, Garcia-Galera del Carmen M, Munoz M, Echevarria JM. Comparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection. J Med Virol. 2015;87(11):1934-1939.
Abravanel F, Chapuy-Regaud S, Lhomme S, et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. J Clin Virol. 2013;58(4):624-628.
Myint KS, Endy TP, Shrestha MP, et al. Hepatitis E antibody kinetics in Nepalese patients. Trans R Soc Trop Med Hyg. 2006;100(10):938-941.
Zhang F, Li X, Li Z, et al. Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E. J Med Virol. 2006;78(11):1441-1448.
Zhao C, Geng Y, Harrison TJ, Huang W, Song A, Wang Y. Evaluation of an antigen-capture EIA for the diagnosis of hepatitis E virus infection. J Viral Hepat. 2015;22(11):957-963.
Wen GP, Tang ZM, Yang F, et al. A valuable antigen detection method for diagnosis of acute hepatitis E. J Clin Microbiol. 2015;53(3):782-788.
Riveiro-Barciela M, Sauleda S, Quer J, et al. Red blood cell transfusion-transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report. Transfusion. 2017;57(2):244-247.
Baylis SA, Blumel J, Mizusawa S, et al. World Health Organization International Standard to harmonize assays for detection of hepatitis E virus RNA. Emerg Infect Dis. 2013;19(5):729-735.
Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857-872.
Pas SD, Streefkerk RH, Pronk M, et al. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol. 2013;58(4):629-634.
Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012;367(13):1237-1244.
Said B, Ijaz S, Chand MA, Kafatos G, Tedder R, Morgan D. Hepatitis E virus in England and Wales: indigenous infection is associated with the consumption of processed pork products. Epidemiol Infect. 2014;142(7):1467-1475.
Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26(10):1429-1435.
Behrendt P, Bremer B, Todt D, et al. Hepatitis E virus (HEV) ORF2 antigen levels differentiate between acute and chronic HEV infection. J Infect Dis. 2016;214(3):361-368.